B. Pangallo

发表

A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.

R. Findling, J. Strawn, Qi Zhang, 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.

J. March, Qi Zhang, G. Emslie, 2014, Journal of child and adolescent psychopharmacology.

Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials

M. Detke, S. Kennedy, Qi Zhang, 2010, Current medical research and opinion.

Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence.

M. Detke, N. Zinner, L. Viktrup, 2004, Primary care companion to the Journal of clinical psychiatry.

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials

K. Reich, R. Langley, R. Langley, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.

S. Ball, P. Liu, C. Goldberger, 2016, The Journal of clinical psychiatry.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and

M. Dougados, J. Reveille, R. Landewé, 2018, The Lancet.

Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.

J. March, Qi Zhang, G. Emslie, 2015, Journal of child and adolescent psychopharmacology.

Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.

M. Ohtsuki, M. Gooderham, S. Ball, 2018, Journal of drugs in dermatology : JDD.

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)

L. Mallbris, F. Zhao, K. Callis Duffin, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression.

R. Tamura, J. March, C. Kratochvil, 2012, Journal of child and adolescent psychopharmacology.

A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.

J. March, Qi Zhang, G. Emslie, 2014, Journal of child and adolescent psychopharmacology.

Evaluation of the Effects of Duloxetine and Escitalopram on 24-Hour Heart Rate Variability: A Mechanistic Study Using Heart Rate Variability as a Pharmacodynamic Measure

M. Detke, R. Kovacs, M. Mitchell, 2013, Journal of clinical psychopharmacology.

Hepatic effects of duloxetine-I: non-clinical and clinical trial data.

J. Wernicke, J. Henck, J. Uetrecht, 2008, Current drug safety.

A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.

J. Russell, C. Goldberger, D. D'souza, 2011, Journal of psychiatric research.

Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies.

T. Wise, C. Wiltse, B. Pangallo, 2006, Primary care companion to the Journal of clinical psychiatry.

Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine

M. Thase, M. Detke, C. Mallinckrodt, 2005, Journal of clinical psychopharmacology.

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

R. Romiti, F. Valenzuela, E. Chouela, 2019, The British journal of dermatology.

Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects

M. Detke, C. Nemeroff, R. Dean, 2014, Journal of clinical psychopharmacology.

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience

Fangyi Zhao, D. Shrom, Kristina Callis Duffin, 2016, Medical devices.

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

C. Goldberger, Peng Liu, Qi Zhang, 2015, Drugs in context.

Safety and Tolerability of Edivoxetine for Long-Term Treatment of Major Depressive Disorder in Adult Patients

W. White, C. Goldberger, M. Bangs, 2014 .

Efficacy and Safety of Duloxetine 30 mg/d in Patients With Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Study

L. Arnold, Shuyu Zhang, B. Pangallo, 2012, The Clinical journal of pain.

Efficacy and Safety of Duloxetine 30 mg/d in Patients With Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Study

L. Arnold, Shuyu Zhang, B. Pangallo, 2012, The Clinical journal of pain.